Literatur
-
1
Creutzfeldt W.
The incretin concept today.
Diabetologia.
1979;
16
75-85
-
2
Deacon C F.
MK-431 (Merck).
Curr Opin Investig Drugs.
2005;
6
419-426
-
3
Deacon C F, Nauck M A, Toft-Nielsen M. et al .
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.
Diabetes.
1995;
44
1126-1131
-
4
Del Prato S, Marchetti P.
Beta- and alpha-cell dysfunction in type 2 diabetes.
Horm Metab Res.
2004;
36
775-781
-
5
Drucker D J, Nauck M A.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet.
2006;
368
1696-1705
-
6
Farilla L, Bulotta A, Hirshberg B. et al .
Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets.
Endocrinology.
2003;
144
5149-5158
-
7
Gallwitz B.
Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Minerva Endocrinol.
2006;
31
133-147
-
8
Gallwitz B.
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Int J Clin Pract.
2006;
60
1654-1661
-
9
Green B D, Flatt P R, Bailey C J.
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Diab Vasc Dis Res.
2006;
3
159-165
-
10
Holmann R R.
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.
Diabetes Res Clin Pract.
1998;
40 (Suppl)
S 21-S 25
-
11
Kendall D M, Kim D, Maggs D.
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
Diabetes Technol Ther.
2006;
8
385-396
-
12
Mari A, Sallas W M, He Y L. et al .
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
J Clin Endocrinol Metab.
2005;
90
4888-4894
-
13
Mentlein R, Gallwitz B, Schmidt W E.
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
Eur J Biochem.
1993;
214
829-835
-
14
Nauck M, Stöckmann F, Ebert R. et al .
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
Diabetologia.
1986;
29
46-52
-
15
Nauck M A, Heimesaat M M, Orskov C. et al .
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
J Clin Invest.
1993;
91
301-307
-
16
Ristic S, Bates P C.
Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.
Drugs Today.
2006;
42
519-531
-
17
Turner R C, Cull C A, Frighi V. et al .
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
JAMA.
1999;
281
2005-2012
-
18
Unger R H.
Glucagon physiology and pathophysiology.
New Engl J Med.
1971;
285
443-449
-
19
Vilsboll T.
Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Expert Opin Investig Drugs.
2007;
16
231-237
Prof. Dr. med. Baptist Gallwitz
Medizinische Klinik IV · Universitätsklinikum Tübingen
Otfried-Müller-Straße 10
72076 Tübingen
Email: baptist.gallwitz@med.uni-tuebingen.de
